ArticleMedComm2025

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells.

Michaël Constantinides et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.